{"product_id":"dexcom-bcg-matrix","title":"DexCom Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix: Prioritizing DexCom's Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDexCom's BCG Matrix snapshot maps CGM product lines by market growth and relative share, distinguishing likely Stars, Cash Cows and lower-growth offerings to clarify investment, harvest or divest priorities. This preview summarizes competitive position and growth dynamics; the full BCG Matrix delivers quadrant-level data, prioritized recommendations and ready-to-use visuals. Access the complete report for a Word analysis and an Excel summary that translate these insights into resource-allocation decisions and tactical next steps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom G7 Global Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe G7 system is Dexcom's primary growth driver by late 2025, holding roughly 55% share of the intensive insulin-delivery CGM segment and driving 2025 product revenue growth of ~18% year-over-year to $3.2B.\u003c\/p\u003e\n\u003cp\u003eIts 30-minute warm-up and MARD ~7% have outpaced rivals, helping global shipments rise 26% in 2024-25 and expanding presence in 24 new markets. \u003c\/p\u003e\n\u003cp\u003eDexcom increased R\u0026amp;D and SG\u0026amp;A spend to $1.1B in 2025, funding marketing and pivotal trials to defend leadership versus Abbott and Medtronic. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStelo Glucose Biosensor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLaunched in 2023 to target the 400+ million global Type 2 non-insulin market, Stelo Glucose Biosensor became a star by late 2025 with estimated 2025 retail sales of $220M and 35% month-on-month unit growth among OTC buyers.\u003c\/p\u003e\n\u003cp\u003eIt serves health-conscious consumers and early-stage diabetics, capturing ~12% share of OTC CGM units in the US by Q4 2025 while conversion-to-subscription rates hit 18%.\u003c\/p\u003e\n\u003cp\u003eHigh promotional spend (approx $60M in 2025) pressures margins short-term, but unit economics (LTV\/CAC ~3.5x) and rapid scale point to material cash generation from 2026 onward.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Insulin Delivery Integrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom's automated insulin delivery integrations with pump makers Tandem (Tandem Diabetes Care) and Insulet (Insulet Corporation) position its G6\/G7 sensors as the ecosystem brain, supporting ~60-70% share of U.S. closed‑loop systems as of 2025 and driving rapid user growth (~25% YoY in automated users through 2024).\u003c\/p\u003e\n\u003cp\u003eThis segment sits in BCG's Stars: high market share and high growth; it burns R\u0026amp;D and regulatory cash for firmware and interoperability but offers outsized strategic value-contributing an estimated 20-25% of device revenues and improving lifetime customer retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexCom is treating International Emerging Markets (Latin America, SEA, parts of South Asia) as Stars: high-growth diabetes prevalence (+8-10% annual cases regionally; IDF 2025) and rising CGM adoption give DexCom strong early-mover potential as it builds brand and payer relationships.\u003c\/p\u003e\n\u003cp\u003eDexCom is committing heavy capex and opex for local distribution, regulatory approvals, and training-estimated multi-year investment of $200-350M to scale in key markets-so market share gains hinge on sustained spend and local partnerships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: regional diabetes incidence +8-10% (IDF 2025)\u003c\/li\u003e\n\u003cli\u003eEarly mover edge: limited established CGM brands in many countries\u003c\/li\u003e\n\u003cli\u003eRequired spend: $200-350M multi-year deployment\u003c\/li\u003e\n\u003cli\u003eFocus: distribution, regulatory, clinician\/patient education\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom Clarity Data Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexcom Clarity Data Platform has evolved into a leading data-management tool, delivering actionable insights to patients and providers and supporting over 2.1 million active users worldwide as of Q4 2025.\u003c\/p\u003e\n\u003cp\u003eIn the high-growth digital-health analytics market (CAGR ~16% through 2028), Clarity sustains high engagement and a double-digit share of Dexcom ecosystem users, driving recurring device stickiness and higher lifetime value.\u003c\/p\u003e\n\u003cp\u003eThe platform acts as a critical retention hook, so Dexcom must keep investing-estimated $120-160M annual spend-in software engineering and cybersecurity to protect PHI and sustain regulatory compliance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2.1M active users Q4 2025\u003c\/li\u003e\n\u003cli\u003eDigital-health analytics CAGR ~16% to 2028\u003c\/li\u003e\n\u003cli\u003e$120-160M estimated annual platform spend\u003c\/li\u003e\n\u003cli\u003eDrives device stickiness and higher LTV\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Stars Propel $3.2B G7 Growth-Clarity 2.1M Users, $1.1B R\u0026amp;D+SG\u0026amp;A Burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eG7\/G6 sensors, Stelo OTC, international expansion, and Clarity sit in BCG Stars: high market share and high growth, driving ~20-25% of device revenue and ~18% product revenue growth to $3.2B in 2025 while burning R\u0026amp;D\/market spend (~$1.1B R\u0026amp;D+SG\u0026amp;A; $60M Stelo promos; $200-350M intl capex). Clarity: 2.1M users; $120-160M annual platform spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice revenue share from Stars\u003c\/td\u003e\n\u003ctd\u003e20-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG7-driven product rev\u003c\/td\u003e\n\u003ctd\u003e$3.2B (18% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D+SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStelo retail\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClarity users\u003c\/td\u003e\n\u003ctd\u003e2.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl scale spend\u003c\/td\u003e\n\u003ctd\u003e$200-350M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for DexCom: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with investment, hold, or divest recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page DexCom BCG Matrix mapping products by growth and share for quick strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom G6 Mature Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Dexcom G6 remains a cash cow, generating an estimated $2.1 billion in 2025 revenue and serving ~1.2 million active users who have not yet moved to newer models.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D for G6 was amortized years ago, so sensor and transmitter gross margins exceed 60%, giving exceptionally high cash conversion.\u003c\/p\u003e\n\u003cp\u003eThat steady free cash flow-about $800 million in 2025-funds development of next‑gen continuous glucose monitors and biosensors, cutting time‑to‑market risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eType 1 Diabetes Core Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexComs Type 1 diabetes core market is a mature, high-share segment: as of fiscal 2024 DexCom held about 50%-55% U.S. CGM market share in Type 1 patients, with strong brand loyalty and multi-year retention rates above 70% annually.\u003c\/p\u003e\n\u003cp\u003eGrowth is steady, not rapid-Type 1 patient CGM penetration rose ~3-4 percentage points yearly in the U.S. in 2023-24-so this segment functions as a cash cow needing less defensive marketing spend.\u003c\/p\u003e\n\u003cp\u003eRecurring revenue from durable users drove 2024 subscription-like sales stability, contributing to \u0026gt;60% of recurring revenue and helping DexCom service debt and fund R\u0026amp;D; FY2024 revenue was $3.4 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and Government Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom (DexCom, Inc.) secured Medicare coverage for continuous glucose monitoring (CGM) in 2020 and by 2025 reports over 350,000 Medicare beneficiaries using its devices, supporting recurring revenue of roughly $500m-$700m annually from U.S. public payers alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Channel Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe shift from durable medical equipment to pharmacy channels has cut distribution friction for DexCom, improving cash conversion: pharmacy fills now cover an estimated 65-70% of U.S. retail CGM prescriptions (2025 data), shortening payment cycles and reducing accounts receivable days.\u003c\/p\u003e\n\u003cp\u003eThis mature pharmacy model needs less admin overhead and broader patient access-millions gain same-day pickup at \u0026gt;20,000 retail locations-so operating costs per unit fall versus DME logistics.\u003c\/p\u003e\n\u003cp\u003eHigh retail market share lets DexCom collect passive gains with minimal capex; incremental revenue from pharmacy penetration grew ~12% YoY in 2024 without major new infrastructure spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePharmacy fills ~65-70% of U.S. CGM scripts (2025)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;20,000 retail pickup locations\u003c\/li\u003e\n\u003cli\u003e2024 incremental pharmacy revenue +12% YoY\u003c\/li\u003e\n\u003cli\u003eLower AR days and reduced admin per unit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Subscription Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy late 2025 Dexcom's direct-to-consumer subscription billing for long‑term continuous glucose monitor (CGM) users has become a low-cost, high-margin cash cow, producing predictable revenue-subscriptions represented about 42% of U.S. recurring revenue and grew at ~18% YoY in 2024-25.\u003c\/p\u003e\n\u003cp\u003eLow incremental marketing spend cut churn to ~8% annualized and raised lifetime value (LTV) by roughly 25%, while subscriber telemetry trimmed supply-chain costs, improving gross margins by ~220 basis points versus non‑subscribed sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSubscriptions = 42% of U.S. recurring revenue (late 2025)\u003c\/li\u003e\n\u003cli\u003eYoY subscription growth ~18% (2024-25)\u003c\/li\u003e\n\u003cli\u003eChurn ≈ 8% annualized; LTV +25%\u003c\/li\u003e\n\u003cli\u003eSupply-chain margin improvement ≈ 220 bps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom's G6: $2.1B revenue, $800M FCF - subscription-powered cash machine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom's G6 and subscription base are cash cows: ~$2.1B revenue (2025), ~$800M free cash flow (2025), \u0026gt;60% gross margins on sensors, subscriptions ≈42% of U.S. recurring revenue and ~8% churn, pharmacy fills 65-70% of scripts supporting predictable, low‑capex cash generation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024-25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eG6 revenue\u003c\/td\u003e\n\u003ctd\u003e$2.1B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree cash flow\u003c\/td\u003e\n\u003ctd\u003e$800M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensor gross margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscriptions share\u003c\/td\u003e\n\u003ctd\u003e42% U.S. recurring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChurn\u003c\/td\u003e\n\u003ctd\u003e~8% annual\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy fills\u003c\/td\u003e\n\u003ctd\u003e65-70% U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eDexCom BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact DexCom BCG Matrix you'll receive after purchase-no watermarks, no draft notes-just a fully formatted, analysis-ready report designed for strategic use by investors and corporate teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy G4 and G5 Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy G4 and G5 systems held under 1% of DexCom's installed base by end-2025, showing near-zero unit growth and negligible revenue contribution versus G6\/G7; sensor shipments for legacy units dropped ~92% from 2020-2025. \u003c\/p\u003e\n\u003cp\u003eThey are obsolete next to factory-calibrated G6\/G7, drive rising support costs per device (estimated 3-5x higher), and, given low ARR impact, are ideal candidates for full sunsetting in 2026 to cut support spend and simplify supply chains. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandalone Handheld Receivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandalone handheld receivers rank as Dogs: over 75% of DexCom users (Q4 2025, company filings) access CGM data via smartphones or smartwatches, leaving receiver shipments down \u0026gt;60% vs 2019 and negligible revenue growth; production costs per unit remain ~30-40% higher than smartphone-enabled kits, turning receivers into a cash trap with low margin and poor ROI in a mobile-first market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManual Calibration Sensors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManual calibration sensors-early DexCom models requiring daily fingerstick calibration-now hold near-zero market share as factory-calibrated sensors (no-fingerstick) captured ~88% of CGM unit shipments by 2024, per industry reports; revenue from manual sensors is negligible and declining.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Integrated Research Hardware\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-integrated research hardware-specialized Dexcom units built for niche academic studies-sit in the Dogs quadrant with low market share and low growth, selling under a few hundred units annually and tying up 0.5-1.5% of production capacity.\u003c\/p\u003e\n\u003cp\u003eThese configs need custom manufacture and support, driving per-unit costs 2-3x higher than mass-market G7\/G6 lines; they often only break even and divert ~$4-8M\/year from core CGM scale-up efforts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow volumes: \u0026lt;100-300 units\/year\u003c\/li\u003e\n\u003cli\u003eHigher cost: 2-3x per-unit vs mass-market\u003c\/li\u003e\n\u003cli\u003eCapacity drain: 0.5-1.5% of output\u003c\/li\u003e\n\u003cli\u003eAnnual cost diversion: $4-8M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-Generation Transmitter Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFirst-generation, bulky transmitters are moving to Dogs in DexComs BCG matrix: G7's fully disposable, integrated transmitter reduced part count and manufacturing cost per unit by ~30% vs G6, cutting legacy transmitter volumes 65% in 2024 and shrinking market share to under 10% of DexCom shipments.\u003c\/p\u003e\n\u003cp\u003eThese legacy components carry high overhead, no growth runway, and are being phased out by management; R\u0026amp;D and capital spend shifted to G7 and future models, so legacy transmitters are cash drains with minimal replacement demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh manufacturing overhead; ~30% higher cost\/unit vs integrated G7\u003c\/li\u003e\n\u003cli\u003eVolume decline: ~65% drop in 2024 vs prior gen\u003c\/li\u003e\n\u003cli\u003eMarket share \u0026lt;10% of DexCom shipments (2024)\u003c\/li\u003e\n\u003cli\u003eNo growth prospects; management redirecting capex to G7\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSunset legacy G4-G5, receivers \u0026amp; transmitters in 2026 to save $8-12M\/year\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: legacy G4\/G5, handheld receivers, manual-cal sensors, niche research units, and first-gen transmitters hold \u0026lt;1-10% share, \u0026lt;0%-1% CAGR, and drag margins by 30-300% higher per-unit cost; recommended full sunsetting in 2026 to save ~$8-12M\/year in support and free capacity for G7 scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eCost vs G7\u003c\/th\u003e\n\u003cth\u003eAnnual drag\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy G4\/G5\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e~0%\u003c\/td\u003e\n\u003ctd\u003e3-5x\u003c\/td\u003e\n\u003ctd\u003e$3-5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReceivers\u003c\/td\u003e\n\u003ctd\u003e~\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003e-5%-0%\u003c\/td\u003e\n\u003ctd\u003e30-40%↑\u003c\/td\u003e\n\u003ctd\u003e$2-4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManual sensors\u003c\/td\u003e\n\u003ctd\u003e≈0%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003en\/a\u003c\/td\u003e\n\u003ctd\u003enegligible\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch units\u003c\/td\u003e\n\u003ctd\u003e100-300\/yr\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e2-3x\u003c\/td\u003e\n\u003ctd\u003e$4-8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy transmitters\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003e-65% (2024)\u003c\/td\u003e\n\u003ctd\u003e~30%↑\u003c\/td\u003e\n\u003ctd\u003eincluded\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-Patient Hospital Monitoring Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom is piloting continuous glucose monitor (CGM) use for in-patient monitoring to replace nursing fingersticks, addressing a US hospital glucose monitoring market estimated at $3.5-4.2 billion by 2028 (Grand View Research). \u003c\/p\u003e\n\u003cp\u003eAdoption is low today-pilot coverage \u0026lt;5% of US hospitals-because clinical protocols and FDA guidance for inpatient CGM lag, and rollout needs capital for devices, staff training, and IT integration. \u003c\/p\u003e\n\u003cp\u003eIf trials prove outcomes and cost-savings (one 2023 study showed 20% fewer hypoglycemic events), this segment could become a Star, but returns remain uncertain and require sustained investment. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGestational Diabetes Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom is targeting gestational diabetes as a high-growth niche for temporary continuous glucose monitoring (CGM); CAGR for pregnancy CGM adoption was ~18% 2024-29 with addressable market ~1.2M pregnancies annually in the US\/EU combined.\u003c\/p\u003e\n\u003cp\u003eCurrent market share remains single-digit versus SMBG (self-monitoring blood glucose); Dexcom holds under 5% penetration in this segment as of Q4 2025.\u003c\/p\u003e\n\u003cp\u003eScaling needs strong clinical advocacy: randomized trials showing A1c\/NDI reductions and targeted payer pilots; marketing must focus on obstetrics workflows and short-term reimbursement codes to convert providers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Analyte Sensor Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom's multi-analyte sensor research-tracking glucose plus lactate or ketones-sits in the Question Marks quadrant: high growth potential but early-stage commercialization. 2024 R\u0026amp;D spend was $433M (23% of revenue), with multi-analyte projects driving a growing share; pilots in 2025 target limited user cohorts under FDA breakthrough pathways. These sensors now burn cash and create little revenue but could expand addressable market beyond $5B CGM by 2030. Success hinges on validation, regulatory clearance, and unit cost parity with single-analyte CGMs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Lifestyle Retail Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDexcom is testing direct-to-consumer retail for non-medical wellness wearables, targeting the $6.5B global wearables fitness market (2024) but holding under 2% share in biohacking\/fitness communities as of 2025.\u003c\/p\u003e\n\u003cp\u003eCompeting with market leaders (Apple, Fitbit) needs consumer branding, retail partnerships, lower price tiers, and marketing focused on lifestyle benefits rather than clinical claims.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$6.5B market (2024)\u003c\/li\u003e\n\u003cli\u003eDexcom \u0026lt;2% share (2025)\u003c\/li\u003e\n\u003cli\u003eRequires new brand, pricing, retail deals\u003c\/li\u003e\n\u003cli\u003eShift from clinical to lifestyle messaging\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeveloping Asia-Pacific Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDeveloping Asia-Pacific Markets: India and China show rising diabetes prevalence-China 11.6% adult prevalence (2024), India 8.9%-but Dexcom's CGM share remains single-digit; revenue exposure under 5% in FY2024, making these markets question marks in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eHigh competition from local, lower-cost CGMs and insulin pump alternatives pressures pricing; China's domestic players cut prices ~20-40% vs western devices, so scaling Dexcom's premium tech is uncertain.\u003c\/p\u003e\n\u003cp\u003eSuccess hinges on local manufacturing, tiered pricing, and regulatory wins (NMPA\/ CDSCO); if Dexcom raises regional share to 15-20% within 3-5 years, the market could move toward star status.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChina adult diabetes 11.6% (2024)\u003c\/li\u003e\n\u003cli\u003eIndia adult diabetes 8.9% (2024)\u003c\/li\u003e\n\u003cli\u003eDexcom FY2024 revenue \u0026lt;5% from APAC\u003c\/li\u003e\n\u003cli\u003eLocal devices 20-40% cheaper\u003c\/li\u003e\n\u003cli\u003ePath to star: 15-20% share in 3-5 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCGM Growth Pivots: Inpatient Trials, Gestational Surge, Multi‑Analyte \u0026amp; APAC Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: in-patient CGM pilots (\u0026lt;5% US hospitals), gestational CGM (~18% CAGR 2024-29; ~1.2M pregnancies addressable), multi-analyte R\u0026amp;D ($433M spend 2024; pilots 2025), DTC wearables (\u0026lt;2% share; $6.5B market 2024), APAC upside (China 11.6% diabetes; India 8.9%; FY2024 APAC revenue \u0026lt;5%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024-25 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInpatient CGM\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5% hospital pilots; market $3.5-4.2B by 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGestational CGM\u003c\/td\u003e\n\u003ctd\u003e~18% CAGR; ~1.2M pregnancies (US\/EU)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMulti-analyte R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$433M R\u0026amp;D (2024); pilots 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC wearables\u003c\/td\u003e\n\u003ctd\u003e$6.5B market (2024); Dexcom \u0026lt;2% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC\u003c\/td\u003e\n\u003ctd\u003eChina 11.6% diabetes (2024); India 8.9%; APAC rev \u0026lt;5% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Porter's Five Forces","offers":[{"title":"Default Title","offer_id":55643115880521,"sku":"dexcom-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0978\/1261\/1145\/files\/dexcom-bcg-matrix.webp?v=1776714667","url":"https:\/\/five-forces.com\/products\/dexcom-bcg-matrix","provider":"Porter’s Five Forces","version":"1.0","type":"link"}